FDA setback for Avadel Pharma's narcolepsy candidate

27 May 2022
avadel_company

Ireland-incorporated Avadel Pharmaceuticals’ (Nasdaq: AVDL) shares fell as much as 63% on Thursday after the company disclosed, in a filing with the US Securities and Exchange Commission (SEC), that it had received a proposed, final label and medication guide for FT218 from the US Food and Drug Administration (FDA).

Avadel is developing FT218, an investigational formulation of sodium oxybate designed to be taken once at bedtime, for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

In addition, the company was notified by the FDA that the FT218 New Drug Application (NDA) patent statement pertaining to US Patent No 8,731,963 (the REMS patent) was deemed inappropriate by the agency. As such, the FDA has requested the company add a certification to the REMS patent to its NDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical